Abstract:ABSTRACT Accurate and timely diagnosis of severe acute respiratory syndrome coronavirus (SARS-CoV) infection is a critical step in preventing another global outbreak. In this study, 829 serum specimens were collected from 643 patients initially reported to be infected with SARS-CoV. The sera were tested for the N protein of SARS-CoV by using an antigen capture enzyme-linked immunosorbent assay (ELISA) based on monoclonal antibodies against the N protein of SARS-CoV and compared to 197 control serum samples from healthy donors and non-SARS febrile patients. The results of the N protein detection analysis were directly related to the serological analysis data. From 27 SARS patients who tested positive with the neutralization test, 100% of the 24 sera collected from 1 to 10 days after the onset of symptoms were positive for the N protein. N protein was not detected beyond day 11 in this group. The positive rates of N protein for sera collected at 1 to 5, 6 to 10, 11 to 15, and 16 to 20 days after the onset of symptoms for 414 samples from 298 serologically confirmed patients were 92.9, 69.8, 36.4, and 21.1%, respectively. For 294 sera from 248 serological test-negative patients, the rates were 25.6, 16.7, 9.3, and 0%, respectively. The N protein was not detected in 66 patients with cases of what was initially suspected to be SARS but serologically proven to be negative for SARS and in 197 serum samples from healthy donors and non-SARS febrile patients. The specificity of the assay was 100%. Furthermore, of 16 sera collected from four patients during the SARS recurrence in Guangzhou, 5 sera collected from 7 to 9 days after the onset of symptoms were positive for the N protein. N protein detection exhibited a high positive rate, 96 to 100%, between day 3 and day 5 after the onset of symptoms for 27 neutralization test-positive SARS patients and 298 serologically confirmed patients. The N protein detection rate continually decreased beginning with day 10, and N protein was not detected beyond day 19 after the onset of symptoms. In conclusion, an antigen capture ELISA reveals a high N protein detection rate in acute-phase sera of patients with SARS, which makes it useful for early diagnosis of SARS.

[A Follow Up Study of Total IgM, IgG, Nucleoprotein and Spike Protein Antibodies Against Severe Acute Respiratory Syndrome (SARS) Coronavirus in Patients with SARS].

Dynamic Changes in IgG and IgM Antibodies As Clinical Indicators During Recovery Stage in Patients with Severe Acute Respiratory Syndrome

Comparison of Immunoglobulin G Responses to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome (SARS) Coronavirus in Patients with SARS.

Dynamic Changes of Viral Load and Antibodies Level in the Patients of Severe Acute Respiratory Syndrome

Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients.

Dynamic Characteristic Analysis of Antibodies in Patients with COVID-19: A 13-Month Study

[Prospective 2-Year Clinical Study of Patients with Positive IgG-antibodies after Recovering from Severe Acute Respiratory Syndrome].

The Dynamic Changes of Serum IgM and IgG Against SARS‐CoV‐2 in Patients with COVID‐19

[Prospective Clinical Study on Serum Immunity in IgG-antibodies Positive Patients Convalescent from Severe Acute Respiratory Syndrome].

Study on the Response of Specific Antibodies Against SARS-CoV in Patients Infected with SARS

The Follow-up Study on the Health Status of Convalescent Patients Recovered from SARS in Tianjin

Characterization of antibody responses to SARS‐CoV‐2 in convalescent COVID‐19 patients

Kinetics Of Severe Acute Respiratory Syndrome (Sars) Coronavirus-Specific Antibodies In 271 Laboratory-Confirmed Cases Of Sars

Detection of Antibodies Against the SARS-CoV-2 Spike Protein and Analysis of the Peripheral Blood Mononuclear Cell Transcriptomic Profile, 15 Years after Recovery from SARS.

Serology of Severe Acute Respiratory Syndrome: Implications for Surveillance and Outcome

Long-Term Persistence of Robust Antibody and Cytotoxic T Cell Responses in Recovered Patients Infected with SARS Coronavirus

Monoclonal Antibody-Based Antigen Capture Enzyme-Linked Immunosorbent Assay Reveals High Sensitivity of the Nucleocapsid Protein in Acute-Phase Sera of Severe Acute Respiratory Syndrome Patients.

IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection

Potent and Persistent Antibody Response in COVID-19 Recovered Patients

Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection

Viral and Antibody Kinetics of COVID-19 Patients with Different Disease Severities in Acute and Convalescent Phases: A 6-Month Follow-Up Study